Canaccord Genuity Reiterates a 'Buy' on Raptor Pharmaceuticals (RPTP); RP103 Launch Prep Underway and Raptor Care Announced

Canaccord Genuity reiterates a 'Buy' on Raptor Pharmaceuticals (NASDAQ: RPTP) price target of $11.00.

Analyst, Ritu Baral, said, "Reiterate rating and price target on high chance of RP103 FQ1/13 US and FQ2/13 EU approval and launch. We expect RP103 to be approved in the US and EU, launching in FQ1/13 and FQ2/13, respectively. We predict manageable payor pushback on premium orphan pricing and quick adoption."

For an analyst ratings summary and ratings history on Raptor Pharmaceuticals click here. For more ratings news on Raptor Pharmaceuticals click here.

Shares of Raptor Pharmaceuticals closed at $4.67 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS